1. Home
  2. MMS vs SLNO Comparison

MMS vs SLNO Comparison

Compare MMS & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMS
  • SLNO
  • Stock Information
  • Founded
  • MMS 1975
  • SLNO 1999
  • Country
  • MMS United States
  • SLNO United States
  • Employees
  • MMS N/A
  • SLNO N/A
  • Industry
  • MMS Business Services
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • MMS Consumer Discretionary
  • SLNO Health Care
  • Exchange
  • MMS Nasdaq
  • SLNO Nasdaq
  • Market Cap
  • MMS 4.0B
  • SLNO 3.8B
  • IPO Year
  • MMS 1997
  • SLNO 2014
  • Fundamental
  • Price
  • MMS $71.63
  • SLNO $82.27
  • Analyst Decision
  • MMS Buy
  • SLNO Strong Buy
  • Analyst Count
  • MMS 1
  • SLNO 9
  • Target Price
  • MMS $90.00
  • SLNO $105.11
  • AVG Volume (30 Days)
  • MMS 391.7K
  • SLNO 1.4M
  • Earning Date
  • MMS 08-06-2025
  • SLNO 08-06-2025
  • Dividend Yield
  • MMS 1.65%
  • SLNO N/A
  • EPS Growth
  • MMS 31.21
  • SLNO N/A
  • EPS
  • MMS 5.00
  • SLNO N/A
  • Revenue
  • MMS $5,395,260,000.00
  • SLNO N/A
  • Revenue This Year
  • MMS $2.13
  • SLNO N/A
  • Revenue Next Year
  • MMS $3.36
  • SLNO N/A
  • P/E Ratio
  • MMS $14.56
  • SLNO N/A
  • Revenue Growth
  • MMS 5.29
  • SLNO N/A
  • 52 Week Low
  • MMS $63.77
  • SLNO $41.50
  • 52 Week High
  • MMS $93.97
  • SLNO $90.32
  • Technical
  • Relative Strength Index (RSI)
  • MMS 52.49
  • SLNO 51.33
  • Support Level
  • MMS $70.61
  • SLNO $79.70
  • Resistance Level
  • MMS $73.79
  • SLNO $90.32
  • Average True Range (ATR)
  • MMS 1.58
  • SLNO 3.66
  • MACD
  • MMS 0.24
  • SLNO -0.41
  • Stochastic Oscillator
  • MMS 69.68
  • SLNO 31.42

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Share on Social Networks: